High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma (vol 100, pg 1444, 2009)

被引:0
|
作者
Marechal, R.
Demetter, P.
Nagy, N.
Berton, A.
Decaestecker, C.
Polus, M.
Closset, J.
Deviere, J.
Salmon, I.
Van Laethem, J-L
机构
关键词
D O I
10.1038/sj.bjc.6605894
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Correction to: British Journal of Cancer (2009) 100, 1444–1451. doi:10.1038/sj.bjc.6605020 Upon publication of this paper in 2009, the authors noticed two errors – one in the abstract and one within the Results section. On page 1444 (Abstract), the seventh sentence should read as follows: ‘In a combining analysis, patients with a CXCR7high/CXCR4high tumour had a significantly shorter DFS and OS than patients with a CXCR4low/CXCR7low tumour’.
引用
收藏
页码:930 / 930
页数:1
相关论文
共 50 条
  • [31] CXCR4 Expression in Patients with High-risk Locally Advanced Renal Cell Carcinoma Can Independently Predict Increased Risk of Disease Progression and Poor Overall Survival
    Li, Xiong
    Huang, Ying
    Xia, Juan
    Chen, Ni
    Wei, Qiang
    Li, Xiang
    Zhang, Peng
    Shen, Peng-Fei
    Wang, Jia
    Zeng, Hao
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2011, 12 (12) : 3313 - 3318
  • [32] DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer
    Drouillard, A.
    Puleo, F.
    Bachet, J. B.
    Ouazzani, S.
    Calomme, A.
    Demetter, P.
    Verset, G.
    Van Laethem, J. L.
    Marechal, R.
    BRITISH JOURNAL OF CANCER, 2016, 115 (10) : 1245 - 1252
  • [33] DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer
    A Drouillard
    F Puleo
    J B Bachet
    S Ouazzani
    A Calomme
    P Demetter
    G Verset
    J L Van Laethem
    R Maréchal
    British Journal of Cancer, 2016, 115 : 1245 - 1252
  • [34] Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases and poor survival
    Xiang, Zuo-lin
    Zeng, Zhao-chong
    Tang, Zhao-you
    Fan, Jia
    Zhuang, Peng-yuan
    Liang, Ying
    Tan, Yun-shan
    He, Jian
    BMC CANCER, 2009, 9
  • [35] Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases and poor survival
    Zuo-lin Xiang
    Zhao-chong Zeng
    Zhao-you Tang
    Jia Fan
    Peng-yuan Zhuang
    Ying Liang
    Yun-shan Tan
    Jian He
    BMC Cancer, 9
  • [36] EVALUATION OF CXCL12 AND CXCR4 TO PREDICT POOR SURVIVAL IN LYMPH NODE-POSITIVE COLORECTAL CANCER PATIENTS
    Zengin, Mehmet
    Dursun, Nevra
    Behzatoglu, Kemal
    Pasaoglu, Husniye Esra
    Benek, Suat
    POLISH JOURNAL OF PATHOLOGY, 2020, 71 (04) : 328 - 338
  • [37] High expression levels of CXCL12 and CXCR4 predict recurrence of adamantinomatous craniopharyngiomas in children
    Gong, Jian
    Zhang, Haili
    Xing, Shushan
    Li, Chunde
    Ma, Zhenyu
    Jia, Ge
    Hu, Wanning
    CANCER BIOMARKERS, 2014, 14 (04) : 241 - 251
  • [38] Preferential expression of chemokine receptor CXCR4 by highly malignant human gliomas and its association with poor patient survival
    Bian, Xiu-Wu
    Yang, Shi-Xin
    Chen, Lian-Hong
    Ping, Yi-Fang
    Zhou, Xiang-Dong
    Wang, Qing-Liang
    Jiang, Xue-Feng
    Gong, Wanghua
    Xiao, Hua-Liang
    Du, Lin-Lin
    Chen, Zi-Qiang
    Zhao, Wen
    Shi, Ling-Quan
    Wang, Ji Ming
    NEUROSURGERY, 2007, 61 (03) : 570 - 578
  • [39] High Expression of Survivin Is Prognostic of Shorter Survival but Not Predictive of Adjuvant Gemcitabine Benefit in Patients with Resected Pancreatic Adenocarcinoma
    Xie, Hao
    Jiang, Wei
    Xiao, Shu-Yuan
    Liu, Xiuli
    JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2013, 61 (02) : 148 - 155
  • [40] Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptor (vol 88, pg 1243, 2010)
    Yadav, Vivek R.
    Sung, Bokyung
    Prasad, Sahdeo
    Kannappan, Ramaswamy
    Cho, Sung-Gook
    Liu, Mingyao
    Chaturvedi, Madan M.
    Aggarwal, Bharat B.
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2013, 91 (03): : 407 - 408